Figure 1. The age structure of patients treated with
remdesivir during Delta (n=490) and Omicron (n=272) surges.
Comorbidities were significantly more frequently reported during the
Omicron prevalence period (75.5 vs. 93%, p<0.001), and these
patients significantly more often presented with vascular diseases such
as stroke (3.1 vs. 12.5%, p<0.001), ischemic heart disease
(9.4 vs. 23.5%, p<0.001) (Table 1).
A comparison of the baseline clinical status of RDV-treated patients
showed a significantly lower percentage of asymptomatic or in stable
condition with saturation >95% (12% vs. 27.9%,
p<0.001) hospitalized during the Delta-dominant period, while
the percentage of patients in unstable condition with saturation ≤95%
or ARDS was significantly higher compared to the Omicron wave (87.9 vs.
72.1%, p<0.001) (Table 2).
Table 2. Baseline clinical status and laboratory parameters
(mean ± SD) of patients hospitalized during Delta and Omicron waves with
regard to RDV treatment.